Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with fewer side effects.

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla ...

Fueled by sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030, Evaluate projects.

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while losing weight, offering a potential solution to one of the key ...

Market Implications: The ongoing study of LY3541860 could influence Eli Lilly’s stock performance and investor sentiment, particularly if the results show promise in treating rheumatoid arthritis.

Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled ‘ACCLAIM-Lp (a)’ to evaluate the efficacy of Lepodisiran in reducing major adverse cardiovascular events in adults ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...